Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Atossa Genetics Inc

Current price
1.37 USD -0.06 USD (-4.20%)
Last closed 1.42 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 214 269 840 USD
Yield for 12 month +91.34 %
21.11.2021 - 28.11.2021

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

4.58 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-23 000 USD

Last Year

-8 000 USD

Current Quarter

-14 000 USD

Last Quarter

-3 000 USD

Key Figures ATOS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -31 354 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -17.84 %
PEG Ratio
Return On Equity TTM -28.8 %
Wall Street Target Price 4.58 USD
Revenue TTM
Book Value 0.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.24 USD
Diluted Eps TTM -0.24 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ATOS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATOS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:12
Payout Ratio
Last Split Date 20.04.2018
Dividend Date 20.04.2018

Stock Valuation ATOS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.8527
Price Book MRQ 2.2991

Financials ATOS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ATOS

For 52 weeks

0.59 USD 2.31 USD
50 Day MA 1.33 USD
Shares Short Prior Month 8 481 482
200 Day MA 0.97 USD
Short Ratio 5.37
Shares Short 10 563 547
Short Percent 8.43 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics